Compare PMM & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMM | SGHT |
|---|---|---|
| Founded | 1989 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.7M | 187.4M |
| IPO Year | N/A | 2021 |
| Metric | PMM | SGHT |
|---|---|---|
| Price | $6.23 | $3.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.08 |
| AVG Volume (30 Days) | 113.0K | ★ 243.4K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | ★ $77,363,000.00 |
| Revenue This Year | N/A | $11.67 |
| Revenue Next Year | N/A | $10.39 |
| P/E Ratio | $26.96 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.70 | $2.40 |
| 52 Week High | $6.52 | $9.24 |
| Indicator | PMM | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 54.78 | 46.50 |
| Support Level | $6.07 | $3.29 |
| Resistance Level | $6.36 | $4.29 |
| Average True Range (ATR) | 0.09 | 0.20 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 87.18 | 58.33 |
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.